Watch GANX. Know when insiders buy.
One email the day a filing lands. Free.
GANX
Gain Therapeutics, Inc.
1.71
−0.03 −1.72%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
64
WATCH · shorts 64
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $74.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$20.1MNET CASH $12.7M52W 1.58 – 4.18SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.7M | −$4.7M | — | -0.11 | −$4.7M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$5.4M | −$5.6M | — | -0.13 | −$4.7M | — | — | May 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.5M | −$4.5M | — | -0.11 | −$4.6M | — | — | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | −$4.8M | −$5.3M | — | -0.15 | −$4.9M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$5.1M | −$5.8M | — | -0.19 | −$5.1M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$4.4M | −$4.5M | — | -0.16 | −$3.8M | — | — | May 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.3M | −$3.8M | — | -0.11 | −$3.5M | $945 | −$3.5M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$4.5M | −$4.5M | — | -0.17 | −$6.1M | $1 | −$6.1M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$8.2M | −$8.1M | — | -0.42 | −$5.8M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$4.4M | −$4M | — | -0.22 | −$3.6M | — | — | May 14 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$4.4M | −$4.7M | — | -0.29 | −$5.7M | $19 | −$5.7M | Mar 27 |
| Q3 2023 · Sep 30 | $0 | — | — | −$4.9M | −$4.7M | — | -0.37 | −$4M | $650 | −$4M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$18.7M | −$20.2M | — | -0.61 | −$18.5M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$20.4M | −$20.4M | — | -0.89 | −$18.9M | $22K | −$18.9M | — | — |
| FY2023 · to Dec 31 | $55K | — | −$22.3M | −$22.3M | -40354.3% | -1.71 | −$18.9M | $15K | −$18.9M | — | — |
| FY2022 · to Dec 31 | $140K | — | −$17.8M | −$17.6M | -12555.1% | -1.48 | −$14.7M | $119K | −$14.8M | — | — |
| FY2021 · to Dec 31 | $165K | — | −$13.8M | −$13.9M | -8418.9% | -1.37 | −$12.4M | $94K | −$12.5M | — | — |
| FY2020 · to Dec 31 | $29K | — | −$3.5M | −$3.6M | -12387.7% | -1.33 | −$3.2M | $21K | −$3.3M | — | — |
Every number comes from Gain Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.